Home / Health / Lilly's Diabetes Drug Mounjaro Outperforms Trulicity in Reducing Heart Attack and Stroke Risk
Lilly's Diabetes Drug Mounjaro Outperforms Trulicity in Reducing Heart Attack and Stroke Risk
31 Jul
Summary
- Mounjaro reduced risk of major adverse heart events by 8% more than Trulicity
- Risk of death from any cause was 16% lower for Mounjaro patients than Trulicity
- Mounjaro is Lilly's newer diabetes drug that also aids in weight loss
On July 31, 2025, pharmaceutical giant Eli Lilly announced that its newer diabetes drug Mounjaro has outperformed its previously top-selling medication Trulicity in reducing the risk of heart attack and stroke. In a large, head-to-head study involving more than 13,000 patients with type 2 diabetes and high cardiovascular risk, Mounjaro reduced the risk of major adverse heart events by 8% more than Trulicity.
Furthermore, the risk of death from any cause was 16% lower for Mounjaro patients compared to those taking Trulicity, though researchers are still studying the data to understand the underlying reasons for this difference. Mounjaro is Lilly's diabetes drug that targets the GLP-1 protein and is also used for weight loss, while Trulicity has been a go-to treatment for preventing heart disease in people with diabetes since 2020.
Trulicity, which first won U.S. approval in 2014, had been Lilly's top seller, reaching peak sales of $7.4 billion in 2022. However, Mounjaro stole that mantle last year with $11.5 billion in sales, more than double Trulicity's $5.2 billion. The new study results are expected to further strengthen Mounjaro's position as a preferred choice for patients with diabetes and high cardiovascular risk.
